← All candidates
Two insider buys in the last year — $492.7K in all.
4 filings on record.
ASNDAscendis Pharma A/S
NasdaqGS · Healthcare · $15.77B
$239.77
-9.49% · Sep 15
Two insider buys in the last year — $492.7K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys● 1 sell
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$15.77B
Float
65.6M
100% public
Short % float
Pro
Price / profit
20.4
Price / future profit
21.6
Price / sales
15.1
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Bienaime Jean Jacques
Bought $270.4K on Aug 14 — 1,100 sh @ $245.85, held direct, 55% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$314.99 avg target
+31.4% vs today · 20 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 2 quarters beat
Q2 '26$0.90 act+$0.13
Q1 '26$0.27 act+$0.35
Coverage
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In FocusSimply Wall St. · 1w agoAscendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement BackingSimply Wall St. · 1w agoTeva claims success in celiac study; BioMarin, Ascendis settle patent disputeBioPharma Dive · 2w agoASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings UnchangedStocktwits · 2w ago
The file stays open
4 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice